Proactive Investors - Run By Investors For Investors

Hat-trick for AstraZeneca as its cancer and anaemia drugs come up trumps in three late-stage trials

Lynparza improved response rates in a subset of ovarian cancer patients, while Roxadustat boosted haemoglobin count in people with anaemia
green traffic light
It has been a busy week for Astra and those two drugs

AstraZeneca PLC (LON:AZN) bagged itself a hat-trick on Thursday after its ovarian cancer and anaemia drugs met their goals in three separate late-stage trials.

The results should be a boon for the blue-chip drugmaker, which has seen patents on several of its blockbuster drugs expire in recent years, severely denting sales.

READ: Chinese regulators approve Astra’s Roxadustat drug

But shares were down 1.5% on Thursday morning to 5,878p as they followed the FTSE 100 lower, which dropped to two-year lows.

Lynparza, Astra’s cancer drug which it is developing alongside Merck, improved response rates in patients with relapsed ovarian cancer who had previously received chemotherapy.

The company said it will discuss the results with US regulators, who recently approved Lynparza as a first-line treatment in adults with a slightly different type of ovarian cancer.

As for AstraZeneca’s Roxadustat anaemia treatment, that also met its primary endpoint in two separate trials exploring its effectiveness in boosting haemoglobin count in patients with the blood disorder.

It marks a successful week for the drug, which was approved for use in China on Tuesday.

View full AZN profile View Profile

AstraZeneca Timeline

Related Articles

blood
June 21 2019
Belgium-based company’s Nu.Q test screens for colorectal and prostate cancers, and may have the potential to detect ovarian disease endometriosis
Challenge trials can speed up vaccine development
May 30 2019
The challenge trial charts the entire disease life cycle from healthy to sick and back to health.
Scientists in a lab
January 31 2019
CEO Gary Phillips says Pharmaxis’ healthy cash balance gives it time to choose between in-house and partnering options.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use